$CDXC
ChromaDex Corp. Stock $cdxc

$cdxc Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000165495421005211 Filed on May 06, 2021

Income Statement

Concept	2021 Q1	2020 Q1
Revenue	$14.68M	$14.35M
YoY Change	2.36%	42.74%
Cost Of Revenue	$5.449M	$6.034M
YoY Change	-9.7%	27.03%
Gross Profit	$9.234M	$8.311M
YoY Change	11.11%	56.81%
Gross Profit Margin	62.89%	57.94%
Selling, General & Admin	$15.81M	$13.28M
YoY Change	19.03%	6.17%
% of Gross Profit	171.2%	159.81%
Research & Development	$787.0K	$919.0K
YoY Change	-14.36%	-21.45%
% of Gross Profit	8.52%	11.06%
Depreciation & Amortization	$221.0K	$214.0K
YoY Change	3.27%	-6.96%
% of Gross Profit	2.39%	2.57%
Operating Expenses	$16.60M	$14.20M
YoY Change	16.87%	3.88%
Operating Profit	-$7.362M	-$5.890M
YoY Change	24.99%	-29.63%
Interest Expense	$19.00K	$12.00K
YoY Change	58.33%	-70.0%
% of Operating Profit
Other Income/Expense, Net	-$19.00K	-$12.00K
YoY Change	58.33%
Pretax Income	-$7.380M	-$5.900M
YoY Change	25.08%	-29.26%
Income Tax
% Of Pretax Income
Net Earnings	-$7.381M	-$5.902M
YoY Change	25.06%	-29.23%
Net Earnings / Revenue	-50.27%	-41.14%
Basic Earnings Per Share	-$0.12
Diluted Earnings Per Share	-$0.12	-$98.70K
COMMON SHARES
Basic Shares Outstanding	64.16M shares
Diluted Shares Outstanding	64.16M shares

Balance Sheet

Concept	2021 Q1	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$44.69M	$13.61M
YoY Change	228.36%	-29.59%
Cash & Equivalents	$44.69M	$13.61M
Short-Term Investments
Other Short-Term Assets	$1.120M	$700.0K
YoY Change	60.0%	-2.78%
Inventory	$12.76M	$11.28M
Prepaid Expenses
Receivables	$3.350M	$3.060M
Other Receivables	$1.300M	$500.0K
Total Short-Term Assets	$63.22M	$29.15M
YoY Change	116.87%	-16.19%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.058M	$4.410M
YoY Change	-30.66%	-12.67%
Goodwill
YoY Change
Intangibles	$1.022M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$594.0K	$800.0K
YoY Change	-25.75%	31.15%
Total Long-Term Assets	$5.774M	$6.460M
YoY Change	-10.62%	-9.65%
TOTAL ASSETS
Total Short-Term Assets	$63.22M	$29.15M
Total Long-Term Assets	$5.774M	$6.460M
Total Assets	$68.99M	$35.61M
YoY Change	93.75%	-15.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.69M	$8.160M
YoY Change	43.3%	-16.31%
Accrued Expenses	$7.328M	$5.860M
YoY Change	25.05%	11.2%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$20.00K	$210.0K
YoY Change	-90.48%	31.25%
Total Short-Term Liabilities	$19.76M	$14.47M
YoY Change	36.53%	-6.95%
LONG-TERM LIABILITIES
Long-Term Debt	$20.00K	$40.00K
YoY Change	-50.0%	-55.56%
Other Long-Term Liabilities	$5.390M	$4.560M
YoY Change	18.2%	-14.12%
Total Long-Term Liabilities	$5.410M	$4.600M
YoY Change	17.61%	-14.81%
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.76M	$14.47M
Total Long-Term Liabilities	$5.410M	$4.600M
Total Liabilities	$25.16M	$19.06M
YoY Change	32.01%	-9.02%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$43.83M	$16.55M
YoY Change
Total Liabilities & Shareholders Equity	$68.99M	$35.61M
YoY Change	93.74%	-15.07%

Cashflow Statement

Concept	2021 Q1	2020 Q1
OPERATING ACTIVITIES
Net Income	-$7.381M	-$5.902M
YoY Change	25.06%	-29.23%
Depreciation, Depletion And Amortization	$221.0K	$214.0K
YoY Change	3.27%	-6.96%
Cash From Operating Activities	-$5.405M	-$5.221M
YoY Change	3.52%	71.18%
INVESTING ACTIVITIES
Capital Expenditures	-$50.00K	-$20.00K
YoY Change	150.0%	-92.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$10.00K
YoY Change	-100.0%	-80.0%
Cash From Investing Activities	-$46.00K	-$20.00K
YoY Change	130.0%	-93.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$24.87M	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$33.45M	$37.00K
YoY Change	90291.89%	-38.33%
NET CHANGE
Cash From Operating Activities	-$5.405M	-$5.221M
Cash From Investing Activities	-$46.00K	-$20.00K
Cash From Financing Activities	$33.45M	$37.00K
Net Change In Cash	$27.99M	-$5.204M
YoY Change	-637.93%	58.18%
FREE CASH FLOW
Cash From Operating Activities	-$5.405M	-$5.221M
Capital Expenditures	-$50.00K	-$20.00K
Free Cash Flow	-$5.355M	-$5.201M
YoY Change	2.96%	85.75%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	19756000	USD
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	67932548	shares
CY2021Q1	us-gaap	Restricted Cash RestrictedCash	200000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	44691000	USD
CY2021Q1	cdcx	Trade Receivables Net Of Allowances TradeReceivablesNetOfAllowances	4647000	USD
CY2020Q4	cdcx	Trade Receivables Net Of Allowances TradeReceivablesNetOfAllowances	2694000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	12762000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	1119000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	63219000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3058000	USD
CY2021Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1022000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1100000	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	594000	USD
CY2021Q1	us-gaap	Assets Assets	68993000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	11693000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7328000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	485000	USD
CY2021Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	19000	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	31000	USD
CY2021Q1	us-gaap	Customer Advances And Deposits CustomerAdvancesAndDeposits	231000	USD
CY2020Q4	us-gaap	Translation Adjustment Functional To Reporting Currency Net Of Tax TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax	-3000	USD
CY2021Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	4441000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	947000	USD
CY2021Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	17000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	25161000	USD
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	61881000	shares
CY2021Q1	us-gaap	Cost Of Revenue CostOfRevenue	5449000	USD
CY2020Q1	us-gaap	Cost Of Revenue CostOfRevenue	6034000	USD
CY2021Q1	us-gaap	Gross Profit GrossProfit	9234000	USD
CY2020Q1	us-gaap	Gross Profit GrossProfit	8311000	USD
CY2021Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6258000	USD
CY2020Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4447000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	824000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	919000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9514000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8835000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	16596000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	14201000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7362000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5890000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	19000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	12000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-19000	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-12000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-7381000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-5902000	USD
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	16424000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	38358000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	62000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	158190000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-141825000	USD
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	64164000	shares
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	59782000	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	16424000	USD
CY2021Q1	cdcx	Issuance Of Common Stock Net Of Offering Costs Amount IssuanceOfCommonStockNetOfOfferingCostsAmount	24871000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	8633000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1284000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	8633000	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	132000	USD
CY2020Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	80000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	33445000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	37000	USD
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-7380000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	43832000	USD
CY2021Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	44000	USD
CY2020Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	15000	USD
CY2021Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	15000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	20445000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	132000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1873000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-5902000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	16548000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-7381000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-5902000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	221000	USD
CY2020Q1	us-gaap	Depreciation Depreciation	214000	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	60000	USD
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	62000	USD
CY2021Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	126000	USD
CY2020Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	92000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1284000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1873000	USD
CY2021Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	14000	USD
CY2020Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-2708000	USD
CY2021Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	28000	USD
CY2020Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	23000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-1967000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	1326000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1079000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	255000	USD
CY2021Q1	cdcx	Implementation Costs For Cloud Computing Arrangement ImplementationCostsForCloudComputingArrangement	-28000	USD
CY2020Q1	cdcx	Implementation Costs For Cloud Computing Arrangement ImplementationCostsForCloudComputingArrangement	0	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	74000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	252000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2248000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1467000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1196000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	833000	USD
CY2021Q1	us-gaap	Increase Decrease In Customer Deposits IncreaseDecreaseInCustomerDeposits	-47000	USD
CY2020Q1	us-gaap	Increase Decrease In Customer Deposits IncreaseDecreaseInCustomerDeposits	69000	USD
CY2021Q1	cdcx	Increase Decrease In Principal Payments On Operating Leases IncreaseDecreaseInPrincipalPaymentsOnOperatingLeases	-154000	USD
CY2020Q1	cdcx	Increase Decrease In Principal Payments On Operating Leases IncreaseDecreaseInPrincipalPaymentsOnOperatingLeases	-143000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5405000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5221000	USD
CY2021Q1	cdcx	Purchases Of Leasehold Improvements And Equipment PurchasesOfLeaseholdImprovementsAndEquipment	-46000	USD
CY2020Q1	cdcx	Purchases Of Leasehold Improvements And Equipment PurchasesOfLeaseholdImprovementsAndEquipment	-15000	USD
CY2021Q1	cdcx	Investment In Other Long Term Assets InvestmentInOtherLongTermAssets	0	USD
CY2020Q1	cdcx	Investment In Other Long Term Assets InvestmentInOtherLongTermAssets	-5000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-46000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-20000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	24871000	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	27994000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-5204000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16697000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18812000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	44691000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13608000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	1000	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	6000	USD
CY2021Q1	cdcx	Financing Lease Obligation Incurred For Purchase Of Computer Equipment And Software FinancingLeaseObligationIncurredForPurchaseOfComputerEquipmentAndSoftware	0	USD
CY2020Q1	cdcx	Financing Lease Obligation Incurred For Purchase Of Computer Equipment And Software FinancingLeaseObligationIncurredForPurchaseOfComputerEquipmentAndSoftware	47000	USD
CY2021Q1	us-gaap	Nature Of Operations NatureOfOperations	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Note 2. Nature of Business</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">ChromaDex is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (“NAD+”), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (“NR”), commercialized as the flagship ingredient NIAGEN®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent portfolio. ChromaDex delivers NIAGEN® as the sole active ingredient in its consumer product TRU NIAGEN®. The Company also has analytical reference standards and services segment, which focuses on natural product fine chemicals (known as “phytochemicals”) and related chemistry services.</p>
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-7381000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-5902000	USD
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	64164000	shares
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	59782000	shares
CY2021Q1	cdcx	Nonvested Shares Of Restricted Stock NonvestedSharesOfRestrictedStock	200000	shares
CY2020Q1	cdcx	Nonvested Shares Of Restricted Stock NonvestedSharesOfRestrictedStock	200000	shares
CY2021Q1	us-gaap	Variable Lease Cost VariableLeaseCost	40000	USD
CY2020Q1	us-gaap	Variable Lease Cost VariableLeaseCost	69000	USD
CY2021Q1	cdcx	Total Operating Lease Expense TotalOperatingLeaseExpense	194000	USD
CY2020Q1	cdcx	Total Operating Lease Expense TotalOperatingLeaseExpense	189000	USD
CY2021Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	62000	USD
CY2020Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	64000	USD
CY2021Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	256000	USD
CY2020Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	253000	USD
CY2021Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3839000	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2358000	USD
CY2021Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	4620000	USD
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	5718000	USD
CY2021Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	3758000	USD
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	3065000	USD
CY2021Q1	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	545000	USD
CY2020Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	542000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	12762000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	11683000	USD
CY2021Q1	cdcx	Operating Lease Right Of Use Assets OperatingLeaseRightOfUseAssets	1100000	USD
CY2021Q1	cdcx	Operating Lease Liabilities OperatingLeaseLiabilities	1400000	USD
CY2021Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	154000	USD
CY2020Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	120000	USD
	cdcx	Weighted Average Remaining Lease Term Years Operating Leases WeightedAverageRemainingLeaseTermYearsOperatingLeases	P2Y6M
CY2020Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.070	pure
CY2021Q1	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	474000	USD
CY2021Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	299000	USD
CY2021Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	308000	USD
CY2021Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	310000	USD
CY2021Q1	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	263000	USD
CY2021Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1654000	USD
CY2021Q1	cdcx	Operating Leases Future Minimum Payments Present Value Of Net Minimum Payments OperatingLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	222000	USD
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1432000	USD
CY2021Q1	cdcx	Operating Lease Liability Less Current Portion OperatingLeaseLiabilityLessCurrentPortion	485000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	947000	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Description ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription	under the 2017 Plan, the Company is authorized to issue shares subject to awards that total no more than the sum of (i) 14,500,000 new shares, (ii) approximately 384,000 unallocated shares remaining available for the grant of new awards under the Second Amended and Restated 2007 Equity Incentive Plan, (iii) any returning shares such as forfeited, cancelled, or expired shares and (iv) 500,000 shares pursuant to an inducement award. The remaining number of shares available for issuance under the 2017 Plan totaled approximately 5.6 million shares at March 31, 2021.
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.73	pure
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.01	pure
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	824000	USD
CY2021Q1	us-gaap	Cost Of Revenue CostOfRevenue	5449000	USD
CY2021Q1	us-gaap	Gross Profit GrossProfit	9234000	USD
CY2021Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6258000	USD
CY2021Q1	us-gaap	Share Price SharePrice	9.34
CY2021Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	10000000.0	USD
CY2021Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y
CY2020Q4	cdcx	Unvested Weighted Average Fair Value Beginning Balance UnvestedWeightedAverageFairValueBeginningBalance	0
CY2021Q1	cdcx	Unvested Shares Granted UnvestedSharesGranted	92000	shares
CY2021Q1	cdcx	Unvested Weighted Average Fair Value Granted UnvestedWeightedAverageFairValueGranted	11.83
CY2021Q1	cdcx	Unvested Weighted Average Fair Value Vested UnvestedWeightedAverageFairValueVested	0
CY2021Q1	cdcx	Unvested Weighted Average Fair Value Forfeited UnvestedWeightedAverageFairValueForfeited	0
CY2021Q1	cdcx	Unvested Shares Expected To Vest UnvestedSharesExpectedToVest	92000	shares
CY2021Q1	cdcx	Unvested Weighted Average Fair Value Ending Balance UnvestedWeightedAverageFairValueEndingBalance	11.83
CY2021Q1	cdcx	Unvested Shares Ending Balance UnvestedSharesEndingBalance	92000	shares
CY2021Q1	cdcx	Unvested Weighted Average Fair Value Expected To Vest UnvestedWeightedAverageFairValueExpectedToVest	11.83
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1284000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1873000	USD
CY2021Q1	us-gaap	Revenues Revenues	14683000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9514000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	16596000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7362000	USD
CY2020Q1	us-gaap	Revenues Revenues	14345000	USD
CY2020Q1	us-gaap	Cost Of Revenue CostOfRevenue	6034000	USD
CY2020Q1	us-gaap	Gross Profit GrossProfit	8311000	USD
CY2020Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4447000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	919000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8835000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	14201000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5890000	USD
CY2021Q1	us-gaap	Other Assets OtherAssets	68993000	USD
CY2020Q4	us-gaap	Other Assets OtherAssets	38358000	USD
CY2021Q1	us-gaap	Revenues Revenues	14683000	USD
CY2020Q1	us-gaap	Revenues Revenues	14345000	USD
CY2019Q3	us-gaap	Accounts Receivable From Securitization AccountsReceivableFromSecuritization	1600000	USD

Files In Submission

Name	View Source	Status
0001654954-21-005211-index-headers.html	Edgar Link	pending
0001654954-21-005211-index.html	Edgar Link	pending
0001654954-21-005211.txt	Edgar Link	pending
0001654954-21-005211-xbrl.zip	Edgar Link	pending
cdcx-20210331.xsd	Edgar Link	pending
cdcx-20210331_cal.xml	Edgar Link	unprocessable
cdcx-20210331_def.xml	Edgar Link	unprocessable
cdcx-20210331_lab.xml	Edgar Link	unprocessable
cdcx-20210331_pre.xml	Edgar Link	unprocessable
cdxc_10q.htm	Edgar Link	pending
cdxc_10q_htm.xml	Edgar Link	completed
cdxc_ex102.htm	Edgar Link	pending
cdxc_ex103.htm	Edgar Link	pending
cdxc_ex104.htm	Edgar Link	pending
cdxc_ex311.htm	Edgar Link	pending
cdxc_ex312.htm	Edgar Link	pending
cdxc_ex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CDXC
ChromaDex Corp. Stock $cdxc

2021 Q1 Form 10-Q Financial Statement

#000165495421005211 Filed on May 06, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDXC ChromaDex Corp. Stock $cdxc

2021 Q1 Form 10-Q Financial Statement

#000165495421005211 Filed on May 06, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDXC
ChromaDex Corp. Stock $cdxc